Interview with: Michael Burnet, Chief Executive Officer, Synovo


Published on

Building Bridges from Pre-Clinical to Clinical Studies: Interview with: Michael Burnet, Chief Executive Officer, Synovo, a sponsor company at the marcus evans Discovery Summit 2013, on improving drug development processes.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Interview with: Michael Burnet, Chief Executive Officer, Synovo

  1. 1. Building Bridges from Pre-Clinical to Clinical Studies What are the key developments in high in small companies, where they drug discovery? hav e a mo re s i m p l e cor por a t e environment to navigate. We now understand what genetic variations exist in the population and Drug discovery scientists should have are in a position to produce some of this in mind when allocating their capital that variation in cell-based systems. The and looking for the right people to work goal is to work with samples that are with. truly representative of patients. How could the cost of drug development be reduced?Interview with: M i c h a e l Burnet, The costs are twofold. First, the sheerChief Executive Officer, Synovo size of the population required to seeThe most powerful drug discovery the economic benefit that the reimbursement authorities are interested in. There isprocess is in vivo pharmacology, so thechallenge becomes to transit to thesestudies as soon as it is feasible, The second main cost then is that these rather blind trials, which are not very simply norecommends Michael Burnet, ChiefExecutive Officer, Synovo. selective in terms of who is recruited, are bigger than they really need to be and are driven by conflicting factors. way toFrom a sponsor company at the marcusevans Discovery Summit 2013, inMonte Carlo, Monaco, 21 - 22 March, The obvious and clear development is the use of molecular biology to identify appropriate patients, and exploratory or encompassBurnet exchanges ideas for moresuccessful drug development. experimental medicine to learn who the patients are. all of theHow can bridges be built from pre-clinical to clinical studies, toimprove the success probability of a The evolution we expect in intelligent trial design will be to have phases of learning about the drug in which one variationscompound?The key change at the moment is that has more freedom to conduct experimental medicine, and then more intelligent trials with more powerful they need tothere is a renewed interest in studyingother species in the pre-clinical area andusing the genetic and genomic tools diagnoses implicated in that. Any final thoughts? know aboutthat we have to learn about the efficacyof drugs, and place them in the contextof human samples. The key problem is Our experience working with different countries is that the economic withoutselecting drugs that are effective whenthey come to patients, and so it is veryimportant to select and use in vivo differences are becoming less important while the human element more. This means that knowledge and productivity working withmodels carefully.The most powerful drug discovery have become critical, as the goal of modern pharmaceutical research is to develop better products faster. in vivoprocess is in vivo pharmacology. Whilescientists should work with in-vitro This requires smarter people fromsystems, molecular models and various backgrounds working at theirsimplified assays, there is simply no most productive. The idea is to uniteway to encompass all of the variations smart people and give them a flexiblethey need to know about without working environment where they haveworking with in vivo models. the freedom to be clever. They can fly
  2. 2. The Pharma Network – marcus About the Discovery Summit 2013 evans Summits group delivers peer-to-peer information on This unique forum will take place at Le Méridien Beach Plaza, Monte Carlo, Monaco, strategic matters, professional 21 - 22 March, 2013. Offering much more than any conference, exhibition or trade trends and breakthrough show, this exclusive meeting will bring together esteemed industry thought leaders innovations. and solution providers to a highly focused and interactive networking event. The Summit includes presentations and interactive forums on building bridges from pre- clinical to clinical studies and designing open innovation platforms. Please note that the Summit is a closed business event and the Contact number of participants strictly limited. Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits Division Tel: + 357 22 849 313 Email: For more information please send an email to All rights reserved. The above content may be republished or reproduced. Kindly inform us by sending an email to press@marcusevanscy.comAbout SynovoSynovo is a drug discovery services company. It was founded in 2003 and has 30 employees covering synthetic chemistry,analytics and pharmacology. We provide specialised pre-clinical services to Pharma and Biotech clients focusing on drugoptimisation. Our business focus is to provide our clients with an integrated view of drug performance in vivo. We help our clientsby providing fast turn-around on studies.Synovo’s main therapeutic areas are Inflammation, Metabolism/diabetes, Skeleto-Muscular and Pain. Within inflammation, we alsocover cancer microenvironment and aspects of ophthalmology, respiratory and gastroenterology.www.synovo.comAbout marcus evans Summitsmarcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discussstrategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity toindividually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings.For more information, please visit: www.marcusevans.comUpcoming EventsEvolution Summit (North America) - www.evolutionsummit.comEvolution Summit (Europe) - www.evolution-summit.comTo view the web version of this interview, please click here: